Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14030687
Abstract: Simple Summary Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors are successful cancer therapeutics that impair DNA repair machinery, leading to an accumulation of DNA damage and consequently cell death. The shared underlying mechanisms driving malignancy and demyelinating… read more here.
Keywords: demyelinating diseases; cancer; repurposing parp; existing evidence ... See more keywords